MetaCap

Palisade Bio Inc. (PALI)

NASDAQ: PALIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.8399-0.0855 (-9.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PALI stock chart

Technical analysis

Key statistics

All statistics
Market cap
$150.74M
52-week range
0.8381 – 2.86
Day range
0.8381 – 0.96
Volume / Avg
3.19M / 3.19M
Beta
—

52-week range

$0.8381$2.86

PALI stock today

Shares of Palisade Bio (PALI) finished lower on Nov 20 at $0.8399, a drop of 9.24% or $0.0855 per share, versus the S&P 500's 3.70% decline. At this level, PALI sits near the bottom of its 52-week range of $0.8381 to $2.86: 70.6% below the high, set on Apr 22, 2026 and 0.2% above the low. PALI is down 64.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 60.6%.

Palisade Bio trades at 0.9x its trailing twelve-month earnings per share of $0.92.

Summary generated from market data by MetaCap's automated system. Methodology

About Palisade Bio

Company profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. J. D. Finley
Headquarters
Denver, CO
Employees
14

Financial highlights

Full financials

In fiscal 2025, Palisade Bio generated $0 in revenue, up 0.0% from fiscal 2024. Palisade Bio reported a net loss of $16.8 million, compared with a loss of $14.4 million a year earlier. Diluted earnings per share came in at -$0.30.

Palisade Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$0$250.00K$0—
Growth—-100.00%———
Net income$-16.78M$-14.44M$-12.30M$-14.26M$-26.62M
EPS (diluted)$-0.30$-10.19$-27.01$-16.53$-169.74

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$8.70+935.84%

  • Strong buy 3
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $16.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.07 vs $-0.06
Surprise
-16.67%

PALI news

All PALI news

Palisade Bio peers

Health Care sector
PALI peer companies
CompanyPrice% ChgMarket capCompare
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs PALI
TARAProtara Therapeutics Inc.2.28-5.00%$140.38Mvs PALI
CGENCompugen Ltd.1.84-2.13%$174.29Mvs PALI
CMPXCompass Therapeutics Inc.0.6882+1.43%$123.94Mvs PALI
HUMAHumacyte Inc.0.4454-17.90%$123.73Mvs PALI
IVVDInvivyd Inc.0.4127-7.45%$122.01Mvs PALI
ENGNenGene Therapeutics Inc.1.74-1.14%$116.61Mvs PALI
IKTInhibikase Therapeutics Inc.1.32+1.54%$185.16Mvs PALI

Indexes, lists and sector

Palisade Bio stock FAQ

What is Palisade Bio's stock price today?

PALI last traded at $0.8399 as of Nov 20, 4:00 PM EST, down 9.24% on the day. Prices are delayed at least 15 minutes.

Does Palisade Bio pay a dividend?

No. Palisade Bio does not currently pay a regular cash dividend.

What is PALI's P/E ratio?

PALI trades at a trailing P/E ratio of 0.91.

Who is Palisade Bio's CEO?

Mr. J. D. Finley is the chief executive officer of Palisade Bio Inc., which has about 14 employees.

Has PALI ever split its stock?

Yes. The most recent PALI stock split was a 1-for-15 split on Apr 8, 2024, one of 5 splits on record.

What is the PALI 52-week high?

The 52-week high for PALI is $2.86 and the 52-week low is $0.8381. The stock is currently 70.6% below its high.

Compare PALI